Songhua Luan
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial.
Journal: Frontiers in immunology
Published: March 01, 2026
Hematology specialist nurse-led continuity-of-care for high-risk hematopoietic cell transplantation recipients.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: November 18, 2025
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies.
Journal: The Journal of antimicrobial chemotherapy
Published: May 26, 2025
Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes.
Journal: Frontiers in immunology
Published: March 03, 2025
Reduced cytomegalovirus reactivation and viremia without increasing GVHD after URD-PBSCT: A prospective study using targeted ATG dosing strategy.
Journal: Cancer pathogenesis and therapy
Published: January 02, 2025
Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.
Journal: Signal transduction and targeted therapy
Published: May 22, 2024
Patients Beyond the Optimal Range of rATG-AUC Still Benefit from the Targeted Dosing Strategy in Unmanipulated Haplo-PBSCT.
Journal: Transplantation and cellular therapy
Published: May 10, 2024
Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.
Journal: Annals of hematology
Published: January 14, 2024
Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single-arm, phase 2 trial.
Journal: American journal of hematology
Published: April 06, 2023
Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.
Journal: Drug design, development and therapy
Published: December 16, 2021
Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: December 11, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026